Imvax: Imvax™ is a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies. Imvax’s portfolio includes several programs designed to stimulate a patient’s immune system against the entire antigen signature of their tumor. Imvax’s most advanced program is IGV-001 for the treatment of glioblastoma. Imvax’s immunotherapy platform is a multi-step process designed to deliver personalized, whole tumor-derived immunotherapies.